OR WAIT null SECS
New urology products and services from sanofi-aventis, American Medical Systems, Karl Storz Endoscopy-America, Inc., Ethicon Endo-Surgery, Cook Medical, and GE Healthcare.
FDA approves agent for metastatichormone-refractory prostate Ca
Paris-The FDA recently granted marketing authorization for cabazitaxel (Jevtana) injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with docetaxel (Taxotere). Results from a recent phase III clinical trial demonstrated a statistically significantly lower risk of death from mHRPC in patients taking cabazitaxel plus prednisone compared with patients on mitoxantrone (Novantrone) and prednisone.
For more information, visit http://www.sanofi-aventis.com/.
New single-incision sling system granted FDA clearance
Endoscopy firm offers capital equipment info via online portal
El Segundo, CA-Karl Storz Endoscopy-America, Inc. has signed a 3-year agreement with Attainia, an online marketplace for capital equipment, to make information available about key solutions for operating room integration and video imaging products. Attainia's Web-based software applications are meant to enable hospitals, health systems, and equipment planners/architects to manage health care projects and budgets more effectively, according to Karl Storz.
For more information, visit http://www.karlstorz.com/.
Stapler offers system-wide compression, natural articulation
Cincinnati-The Echelon Flex 45 Endopath Stapler is a new endocutter that provides surgeons with improved access and compression when deploying the commonly used 45-mm staple line, according to manufacturer Ethicon Endo-Surgery. The stapler delivers system-wide compression, natural articulation, and optimal staple formation in a variety of tissue thickness. It is used to cut and staple tissue in a variety of surgical procedures, including urologic, gynecologic, and general surgery.
For more information, visit http://www.ethiconendo.com/.
Biopsy forceps are engineered to obtain larger tissue samples
Optical imaging agent helps detect nonmuscle-invasive bladder Ca
Waukesha, WI-The FDA recently approved hexaminolevulinate hydrochloride (Cysview) for the detection of nonmuscle-invasive papillary cancer of the bladder. The optical imaging agent is used with the Karl Storz D-Light C Photodynamic Diagnostic system to perform cystoscopy with the blue light setting as an adjunct to the white light setting, according to GE Healthcare, its manufacturer.
For more information, visit http://www.gehealthcare.com/.